The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
Open accessAbstract
BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the efficacy and safety of self-administered subcutaneous CSL830 in patients with type I or type II hereditary angioedema who had had four or more attacks in a consecutive 2-month period within 3 months before screening. We randomly assigned the patients to one of four treatment sequences in a crossover design, each involving two 16-week treatment periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly followed by placebo, or vice versa. The primary efficacy end point was the number of attacks of angioedema. Secondary efficacy end points were the proportion of patients who had a response (≥50% reduction in the number of attacks with CSL830 as compared with placebo) and the number of times that rescue medication was used. RESULTS: Of the 90 patients who underwent randomization, 79 completed the trial. Both doses of CSL830, as compared with placebo, reduced the rate of attacks of hereditary angioedema (mean difference with 40 IU, -2.42 attacks per month; 95% confidence interval [CI], -3.38 to -1.46; and mean difference with 60 IU, -3.51 attacks per month; 95% CI, -4.21 to -2.81; P<0.001 for both comparisons). Response rates were 76% (95% CI, 62 to 87) in the 40-IU group and 90% (95% CI, 77 to 96) in the 60-IU group. The need for rescue medication was reduced from 5.55 uses per month in the placebo group to 1.13 uses per month in the 40-IU group and from 3.89 uses in the placebo group to 0.32 uses per month in the 60-IU group. Adverse events (most commonly mild and transient local site reactions) occurred in similar proportions of patients who received CSL830 and those who received placebo. CONCLUSIONS: In patients with hereditary angioedema, the prophylactic use of a subcutaneous C1 inhibitor twice weekly significantly reduced the frequency of acute attacks. (Funded by CSL Behring; COMPACT EudraCT number, 2013-000916-10 , and ClinicalTrials.gov number, NCT01912456 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
Self-citationBradykinin and the pathophysiology of angioedema
Cugno, M., Nussberger, J., Cicardi, M., & Agostoni, A. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00162-5 · Cited by 215
Self-citation
Cited by
Maurer, M., Magerl, M., Betschel, S., Aberer, W., Ansotegui, I. J., Aygören‐Pürsün, E., Banerji, A., Bara, N., Boccon‐Gibod, I., Bork, K., et al. (2022) · Allergy · doi:10.1111/all.15214 · Cited by 534
Self-citationMaurer, M., Magerl, M., Ansotegui, I., Aygören‐Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A. S., et al. (2018) · Allergy · doi:10.1111/all.13384 · Cited by 513
Self-citationBusse, P. J., & Christiansen, S. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1808012 · Cited by 445
Complement in cancer: untangling an intricate relationship
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.97 · Cited by 425
Banerji, A., Riedl, M. A., Bernstein, J. A., Cicardi, M., Longhurst, H. J., Zuraw, B. L., Busse, P. J., Anderson, J., Magerl, M., Martinez-Saguer, I., et al. (2018) · JAMA · doi:10.1001/jama.2018.16773 · Cited by 312
Self-citation
Metadata
- Authors
- Longhurst, H., Cicardi, M., Craig, T., Bork, K., Grattan, C., Baker, J., Li, H. H., Reshef, A., Bonner, J., Bernstein, J. A., Anderson, J., Lumry, W. R., Farkas, H., Katelaris, C. H., Sussman, G. L., Jacobs, J., Riedl, M., Manning, M. E., Hebert, J., Keith, P. K., Kivity, S., Neri, S., Levy, D. S., Baeza, M. L., Nathan, R., Schwartz, L. B., Caballero, T., Yang, W., Crisan, I., Hernandez, M. D., Hussain, I., Tarzi, M., Ritchie, B., Králíčková, P., Guilarte, M., Rehman, S. M., Banerji, A., Gower, R. G., Bensen-Kennedy, D., Edelman, J., Feuersenger, H., Lawo, J.-P., Machnig, T., Pawaskar, D., Pragst, I., & Zuraw, B. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-23
- Volume
- 376
- Issue
- 12
- Pages
- 1131-1140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2599824295
- Cited by
- 240
- References
- 2
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. https://app.cochat.ai/papers/10.1056/nejmoa1613627
- The paper
- Longhurst, H., Cicardi, M., Craig, T., Bork, K., Grattan, C., Baker, J., Li, H. H., Reshef, A., Bonner, J., Bernstein, J. A., Anderson, J., Lumry, W. R., Farkas, H., Katelaris, C. H., Sussman, G. L., Jacobs, J., Riedl, M., Manning, M. E., Hebert, J., . . . Zuraw, B. L. (2017). Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1613627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.